ROSEN, A NATIONAL AND LEADING INVESTOR RIGHTS FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

Rosen Law Firm is soliciting investors in Beta Bionics, Inc. (NASDAQ: BBNX) who purchased stock between July 30, 2025 and February 24, 2026 to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its iLet Bionic Pancreas insulin pump, concealing that the FDA had raised serious safety concerns including device malfunctions causing dangerously high insulin dosing and thousands of complaints. The lead plaintiff deadline is November 3, 2026.